Showing results (41-50 of 137) with videos related to

Sort By:
Pageof 14
Annals of Hematology|November 20, 2009
Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myelomaMarta Krejci, Zdenek Adam, Tomas Buchler, et al.
In Vivo (Athens, Greece)|August 19, 2021
Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR InhibitorsJindrich Kopecky, Ondrej Kubecek, Tomas Buchler, et al.
Urologic Oncology|December 11, 2013
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokinesAlexandr Poprach, Tomas Pavlik, Bohuslav Melichar, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 1, 2017
Locally advanced breast cancer in elderly patientsJana Hornova, Zbynek Bortlicek, Petra Majkova, et al.
Cancer Genomics & Proteomics|August 31, 2019
MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma PatientsJulia Kovacova, Jaroslav Juracek, Alexandr Poprach, et al.
Cancer|April 12, 2011
Detection of second malignancies during long-term follow-up of testicular cancer survivorsTomas Buchler, Petra Kubankova, Ludmila Boublikova, et al.
Annals of Hematology|September 29, 2009
Levels of angiogenic factors in patients with multiple myeloma correlate with treatment responseLudek Pour, Hana Svachova, Zdenek Adam, et al.
BMC Gastroenterology|March 27, 2014
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registryLubomir Slavicek, Tomas Pavlik, Jiri Tomasek, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|November 30, 2020
Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centersIgor Richter, Alexandr Poprach, Anezka Zemankova, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 18, 2017
The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumabOndrej Fiala, Pavel Pitule, Petr Hosek, et al.
Pageof 14